A Phase I Study of [225Ac]-AZD2284 in Patients with Metastatic Castration-Resistant Prostate Cancer

Trial Identifier: D7580C00001
Sponsor: AstraZeneca
Collaborator:
Parexel
Start Date: March 2025
Primary Completion Date: April 2029
Study Completion Date: April 2029
Condition: Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU East Melbourne, AU, 3002
US, Florida Miami, Florida, US, 33165
US, IL Chicago, IL, US, 60637
US, MA Boston, MA, US, 02215
US, NE Omaha, NE, US, 68130
US, NY New York, NY, US, 10032
US, OH Cleveland, OH, US, 44195
US, OR Portland, OR, US, 97239
ZA CapeTown, ZA, 7925
ZA Durban, ZA, 4013
ZA Pretoria, ZA, 181